Sesamolin serves as an MYH14 inhibitor to sensitize endometrial cancer to chemotherapy and endocrine therapy via suppressing MYH9/GSK3β/β-catenin signaling
Article in Cellular & Molecular Biology Letters (May 2024)
The most recent citing publications are shown below. View all 28 publications that cite this research output on Dimensions.
Article in Cellular & Molecular Biology Letters (May 2024)
Article in BMC Complementary Medicine and Therapies (March 2024)
Article in Journal of Biochemical and Molecular Toxicology (March 2024)